The prognostic significance of pretreatment squamous cell carcinoma antigen levels in cervical cancer patients treated by concurrent chemoradiation therapy and a comparison of dosimetric outcomes and clinical toxicities between tomotherapy and volumetric modulated arc therapy

Table 4 Cox proportional hazards regression analysis for locoregional recurrence–free survival

Variable	HR	95% CI	P value
Age ≥ 60 years	1.18	0.39–3.59	0.775
OTT of RT > 61 days	1.32	0.41–4.29	0.641
T3 or T4 disease	2.64	0.88–7.86	0.082
N1 or N2 disease	0.78	0.24–2.58	0.688
Pretreatment SCC Ag > 10 ng/mL	3.48	1.07–11.26	0.038
Post-treatment SCC Ag > 1.5 ng/mL	0.71	0.15–3.35	0.667
EQD2 of Point A ≥ 81 Gy	1.16	0.35–3.82	0.804
RT technique^a			0.389
VMAT	0.87	0.09–8.26	0.905
Tomotherapy	2.10	0.24–18.58	0.504

HR hazard ratio, CI confidence interval, OTT overall treatment time, RT radiation therapy, SCC Ag squamous cell carcinoma antigen, EQD2 equivalent dose in 2-Gy fractions, VMAT volumetric modulated arc therapy
^aReference category: 3DCRT, three-dimensional conformal radiation therapy

ISSN: 1748-717X